VYNE Therapeutics Inc. (VYNE)
NASDAQ·Healthcare·Biotechnology
$27.80
—
Mkt Cap $9.75M
Analyst Ratings
No recent rating data.
Price Target (1 analysts)
$5.75
Range $5.75 – $5.75
Implied Upside
-79.3%
Consensus $5.75 vs current $27.80
NASDAQ·Healthcare·Biotechnology
$27.80
—
Mkt Cap $9.75M
No recent rating data.
Price Target (1 analysts)
$5.75
Range $5.75 – $5.75
-79.3%
Consensus $5.75 vs current $27.80